405 related articles for article (PubMed ID: 11279633)
1. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Ruiz-Argüelles GJ; Gómez-Almaguer D; Ruiz-Argüelles A; González-Llano O; Cantú OG; Jaime-Pérez JC
Am J Hematol; 2001 Apr; 66(4):241-4. PubMed ID: 11279633
[TBL] [Abstract][Full Text] [Related]
2. [Peripheral blood hematopoietic cell transplant using immunosuppressive chemotherapy without bone marrow destruction: "minitransplant"].
Gómez-Almaguer D; Ruiz-Argüelles GJ; González-Llano O; Ruiz-Argüelles A; Cantú-Rodríguez OG
Gac Med Mex; 2002; 138(3):235-9. PubMed ID: 12096391
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases.
Gómez-Almaguer D; Ruiz-Argüelles GJ; Ruiz-Argüelles A; González-Llano O; Cantú OE; Hernández NE
Bone Marrow Transplant; 2000 Jan; 25(2):131-3. PubMed ID: 10673669
[TBL] [Abstract][Full Text] [Related]
4. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
[TBL] [Abstract][Full Text] [Related]
6. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Bornhäuser M; Thiede C; Schuler U; Platzbecker U; Freiberg-Richter J; Helwig A; Plettig R; Röllig C; Naumann R; Kroschinsky F; Neubauer A; Ehninger G
Bone Marrow Transplant; 2000 Jul; 26(2):119-25. PubMed ID: 10918420
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
10. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
11. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Shapira MY; Or R; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
Bone Marrow Transplant; 2003 Sep; 32(6):557-61. PubMed ID: 12953126
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
[TBL] [Abstract][Full Text] [Related]
15. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
16. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
18. [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
Wu B; Guo K; Song Z; Yan D; Yang Y; Xiao L
Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):194-7. PubMed ID: 12133456
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
20. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
